Pages that link to "Q31854727"
Jump to navigation
Jump to search
The following pages link to Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers (Q31854727):
Displaying 50 items.
- Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children (Q24197662) (← links)
- Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children (Q24201774) (← links)
- Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children (Q24234581) (← links)
- Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children (Q24235303) (← links)
- Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma (Q24235496) (← links)
- Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma (Q24235964) (← links)
- Combination formoterol and inhaled steroid as maintenance and reliever therapy versus higher dose combination inhaler maintenance for chronic asthma in adults and children (Q24236220) (← links)
- Formoterol versus short-acting beta-agonists as relief medication for chronic asthma (Q24239826) (← links)
- Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children (Q24240464) (← links)
- Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children (Q24241025) (← links)
- Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children (Q24241556) (← links)
- Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children (Q24242173) (← links)
- Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma (Q24245383) (← links)
- Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma (Q24245643) (← links)
- Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults (Q24245719) (← links)
- Fluticasone/formoterol: a new single-aerosol combination therapy for patients with asthma (Q26826850) (← links)
- Inhaled budesonide/formoterol combination (Q32058574) (← links)
- Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial (Q34451200) (← links)
- Seretide for obstructive lung disease (Q34544756) (← links)
- Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence (Q34623797) (← links)
- Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety. (Q34644636) (← links)
- Inhaled steroid/long-acting beta 2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients (Q35039844) (← links)
- Inhaled corticosteroids plus long-acting beta2-agonists as a combined therapy in asthma (Q35040750) (← links)
- Combination therapy: appropriate for everyone? (Q35180953) (← links)
- Budesonide/formoterol for the treatment of asthma (Q35183771) (← links)
- New strategies in the treatment and prevention of allergic diseases (Q35680646) (← links)
- Budesonide/formoterol: a review of its use in asthma (Q35826295) (← links)
- Combination therapy of long-acting beta agonists and inhaled corticosteroids in the management of chronic asthma (Q36026016) (← links)
- Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma (Q36326508) (← links)
- Effects of two inhaled corticosteroid/long-acting beta-agonist combinations on small-airway dysfunction in mild asthmatics measured by impulse oscillometry (Q37095507) (← links)
- The effects of long-acting β2-agonists plus inhaled corticosteroids for early reversibility in patients with airway obstruction. (Q37127990) (← links)
- Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma (Q37362634) (← links)
- Evaluation of combination long-acting beta-2 agonists and inhaled glucocorticosteroids for treatment of asthma (Q37556546) (← links)
- Salmeterol/fluticasone propionate: a review of its use in asthma. (Q37589610) (← links)
- Budesonide/formoterol dry powder in asthma: an option for control as maintenance and reliever therapy (Q37678433) (← links)
- Budesonide/formoterol in the treatment of asthma (Q37798026) (← links)
- Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma (Q39290816) (← links)
- Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma (Q39395059) (← links)
- A smarter way to manage asthma with a combination of a long-acting beta(2)-agonist and inhaled corticosteroid (Q42110251) (← links)
- Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-gr (Q42662997) (← links)
- Importance and variability of symptoms in chronic obstructive pulmonary disease. Their significance for treatment (Q42749942) (← links)
- Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study (Q42995911) (← links)
- Budesonide/formoterol in the treatment of asthma (Q43061643) (← links)
- Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma (Q44402329) (← links)
- Audit of budesonide/formoterol prescribing for asthma in community pharmacy in the UK (Q45760683) (← links)
- Onset of effect of budesonide and formoterol administered via one pressurized metered-dose inhaler in patients with asthma previously treated with inhaled corticosteroids (Q46349450) (← links)
- Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids (Q46619161) (← links)
- Real-world effects of two inhaled corticosteroid/long-acting β₂-agonist combinations in the treatment of asthma. (Q53593298) (← links)
- Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma (Q84224029) (← links)
- Benefit:Risk Profile of Budesonide in Obstructive Airways Disease (Q90247731) (← links)